Breaking Finance News

Robert W. Baird recorded NewLink Genetics (NASDAQ:NLNK), scaling down its price target to $8.00 earlier today

Indicating a possible downside of -0.25%, Robert W. Baird reduced the stock price target of NewLink Genetics (NASDAQ:NLNK) to $8.00

On Wednesday June 07, 2017, Zacks Investment Research reported about NewLink Genetics (NASDAQ:NLNK) raised the target price from $0.00 to $12.00 that suggested an upside of 0.09%.

Just yesterday NewLink Genetics (NASDAQ:NLNK) traded -0.90% lower at $10.62. The company’s 50-day moving average is $10.53 and its 200-day moving average is $11.52. With the last stock price close down -4.90% relative to the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the same time. 931,308 shares of the stock were exchanged, down from an average trading volume of 2,532,910

See Chart Below

NewLink Genetics (NASDAQ:NLNK)

With a total market value of $0, NewLink Genetics has with a one year low of $5.90 and a one year high of $25.17 .

A total of 6 firms have reported on the company. 2 brokers rating the company a strong buy, three equity analysts rating the company a buy, one brokerage rating the company a hold, zero brokerages rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $34.33.

More About NewLink Genetics (NASDAQ:NLNK)

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.